See video presentations from Iconovo Capital Markets Day 2021
On May 26th Iconovo held a Capital Markets Day for investors and other stakeholders to Iconovo. If you missed the presentations, you can still…
Iconovo’s high aiming business goals
Biostock published May 25th an article about Iconovo that can be found in its entirety below
Last week, Iconovo announced its financial targets for…
Respiratorius and Iconovo collaborate on inhalation product for COPD
Biostock published May 21th an article about Iconovo that can be found in its entirety below
The two Lund-based development companies Respiratorius…
Iconovo sets ambitious financial targets for 2026
Iconovo AB (publ), which develops complete inhalation products for a global market, today announces its five-year goals for the business. By…
Iconovo and Respiratorius sign agreement for development of inhalation product to treat COPD
Iconovo AB (publ), which develops complete inhalation products for a global market, and Respiratorius AB (publ), which develops drug candidates…
Iconovo’s CEO on the extended agreement with Amneal
Biostock published May 17th an article about Iconovo that can be found in its entirety below
Last week, Iconovo announced that the US and China have…
Iconovo extends agreement with Amneal for generic Symbicort to cover key markets U.S. and China, as well as Nordic sales rights
Iconovo AB (publ), which develops complete inhalation products for a global market, today announced that its collaboration with the U.S. pharmaceutical…
Abbreviated interim report January – March 2021
Strategic innovation generates new agreements
Key figures in TSEK unless otherwise indicated
Jan-Mar 2021
Jan-Mar 2020
Jan-Dec 2020
Net…
Iconovo presents new inhaler ICOpre at RDD
Biostock published April 28th an article about Iconovo that can be found in its entirety below
Iconovo has invested heavily in developing a new pre-metered…
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 70 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se